Drug Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name Nogapendekin alfa inbakicept
Trade Name Anktiva
Synonyms N-803|N803|N 803|nogapendekin alfa|ALT803|ALT 803|ALT-803
Drug Descriptions

Anktiva (nogapendekin alfa inbakicept) is a fusion protein comprising a mutant version of IL-15 with increased activity and IL-15Ra fused to the Fc region of IgG1, which activates CD8+ T-cells and promotes effector activity, potentially resulting in increased antitumor immune response (PMID: 24404427, PMID: 31338557). Anktiva (nogapendekin alfa inbakicept) in combination with BCG is FDA approved for use in patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors (FDA.gov).

DrugClasses
CAS Registry Number 1850381-92-8
NCIT ID C107503

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Aldoxorubicin + Avelumab + Bevacizumab + Capecitabine + Cyclophosphamide + ETBX-011 + ETBX-021 + ETBX-051 + ETBX-061 + Fluorouracil + Gemcitabine + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Nogapendekin alfa inbakicept + Oxaliplatin Aldoxorubicin Avelumab Bevacizumab Capecitabine Cyclophosphamide ETBX-011 ETBX-021 ETBX-051 ETBX-061 Fluorouracil GI-4000 GI-6207 GI-6301 Gemcitabine Leucovorin Nab-paclitaxel Nogapendekin alfa inbakicept Oxaliplatin haNK cells 0 2
Aldoxorubicin + Avelumab + Capecitabine + Cetuximab + Cyclophosphamide + ETBX-011 + ETBX-021 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Nogapendekin alfa inbakicept + Oxaliplatin + Regorafenib + Trastuzumab Aldoxorubicin Avelumab Capecitabine Cetuximab Cyclophosphamide ETBX-011 ETBX-021 ETBX-051 ETBX-061 Fluorouracil GI-4000 GI-6207 GI-6301 Leucovorin Nab-paclitaxel Nogapendekin alfa inbakicept Oxaliplatin Regorafenib Trastuzumab haNK cells 0 1
Aldoxorubicin + Avelumab + Capecitabine + Cetuximab + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Nogapendekin alfa inbakicept + Sorafenib Aldoxorubicin Avelumab Capecitabine Cetuximab Cyclophosphamide ETBX-011 ETBX-051 ETBX-061 Fluorouracil GI-4000 GI-6207 GI-6301 Leucovorin Nab-paclitaxel Nogapendekin alfa inbakicept Sorafenib haNK cells 0 1
Aldoxorubicin + Avelumab + Cetuximab + ETBX-051 + ETBX-061 + GI-6301 + haNK cells + Nogapendekin alfa inbakicept Aldoxorubicin Avelumab Cetuximab ETBX-051 ETBX-061 GI-6301 Nogapendekin alfa inbakicept haNK cells 0 1
Aldoxorubicin + Avelumab + Cisplatin + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6301 + haNK cells + Nogapendekin alfa inbakicept + Paclitaxel Aldoxorubicin Avelumab Cisplatin Cyclophosphamide ETBX-011 ETBX-051 ETBX-061 Fluorouracil GI-4000 GI-6301 Nogapendekin alfa inbakicept Paclitaxel haNK cells 0 1
Aldoxorubicin + Avelumab + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Nogapendekin alfa inbakicept Aldoxorubicin Avelumab Cyclophosphamide ETBX-011 ETBX-051 ETBX-061 Fluorouracil GI-4000 GI-6207 GI-6301 Leucovorin Nab-paclitaxel Nogapendekin alfa inbakicept haNK cells 0 1
Aldoxorubicin + Cyclophosphamide + Gemcitabine + Nab-paclitaxel + Nogapendekin alfa inbakicept Aldoxorubicin Cyclophosphamide Gemcitabine Nab-paclitaxel Nogapendekin alfa inbakicept 0 1
Aldoxorubicin + Cyclophosphamide + Gemcitabine + Nab-paclitaxel + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells Aldoxorubicin Cyclophosphamide Gemcitabine Nab-paclitaxel Nogapendekin alfa inbakicept PD-L1.t-haNK cells 0 1
Atezolizumab + Nogapendekin alfa inbakicept + Ramucirumab Atezolizumab Nogapendekin alfa inbakicept Ramucirumab 0 1
Avelumab + Bevacizumab + ETBX-011 + GI-4000 + Nogapendekin alfa inbakicept Avelumab Bevacizumab ETBX-011 GI-4000 Nogapendekin alfa inbakicept 0 1
Avelumab + haNK cells + Nogapendekin alfa inbakicept Avelumab Nogapendekin alfa inbakicept haNK cells 0 1
BCG solution + Nogapendekin alfa inbakicept BCG solution Nogapendekin alfa inbakicept 0 1
Bintrafusp alfa + CV301 + NHS-IL12 + Nogapendekin alfa inbakicept Bintrafusp alfa CV301 NHS-IL12 Nogapendekin alfa inbakicept 0 1
Bintrafusp alfa + CV301 + Nogapendekin alfa inbakicept Bintrafusp alfa CV301 Nogapendekin alfa inbakicept 0 1
Bintrafusp alfa + Epacadostat + FPV-Brachyury + MVA-BN-Brachyury + Nogapendekin alfa inbakicept Bintrafusp alfa Epacadostat FPV-Brachyury MVA-BN-Brachyury Nogapendekin alfa inbakicept 0 1
Bintrafusp alfa + ETBX-011 + ETBX-051 + ETBX-061 + Nogapendekin alfa inbakicept Bintrafusp alfa ETBX-011 ETBX-051 ETBX-061 Nogapendekin alfa inbakicept 0 1
Bintrafusp alfa + FPV-Brachyury + MVA-BN-Brachyury + Nogapendekin alfa inbakicept Bintrafusp alfa FPV-Brachyury MVA-BN-Brachyury Nogapendekin alfa inbakicept 0 1
Bintrafusp alfa + Nogapendekin alfa inbakicept Bintrafusp alfa Nogapendekin alfa inbakicept 0 2
Carboplatin + Nab-paclitaxel + Nogapendekin alfa inbakicept + Pembrolizumab Carboplatin Nab-paclitaxel Nogapendekin alfa inbakicept Pembrolizumab 0 1
Carboplatin + Nogapendekin alfa inbakicept + Pembrolizumab + Pemetrexed Disodium Carboplatin Nogapendekin alfa inbakicept Pembrolizumab Pemetrexed Disodium 0 1
CD19 t-haNK cells + Nogapendekin alfa inbakicept + Rituximab CD19 t-haNK cells Nogapendekin alfa inbakicept Rituximab 0 1
Cetuximab + haNK cells + Nogapendekin alfa inbakicept Cetuximab Nogapendekin alfa inbakicept haNK cells 0 0
Cetuximab + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells Cetuximab Nogapendekin alfa inbakicept PD-L1.t-haNK cells 0 1
CIML-NK cells + Ipilimumab + Nogapendekin alfa inbakicept CIML-NK cells Ipilimumab Nogapendekin alfa inbakicept 0 1
CIML-NK cells + Nogapendekin alfa inbakicept CIML-NK cells Nogapendekin alfa inbakicept 0 3
Cisplatin + Nogapendekin alfa inbakicept + Pembrolizumab + Pemetrexed Disodium Cisplatin Nogapendekin alfa inbakicept Pembrolizumab Pemetrexed Disodium 0 1
Cyclophosphamide + Fludarabine + Nogapendekin alfa inbakicept Cyclophosphamide Fludarabine Nogapendekin alfa inbakicept 0 2
Cyclophosphamide + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells + Sacituzumab govitecan-hziy Cyclophosphamide Nogapendekin alfa inbakicept PD-L1.t-haNK cells Sacituzumab govitecan-hziy 0 1
Elotuzumab + Melphalan + Nogapendekin alfa inbakicept Elotuzumab Melphalan Nogapendekin alfa inbakicept 0 1
ETBX-011 + ETBX-051 + ETBX-061 + Nogapendekin alfa inbakicept + Retifanlimab ETBX-011 ETBX-051 ETBX-061 Nogapendekin alfa inbakicept Retifanlimab 0 1
ETBX-011 + ETBX-051 + ETBX-061 + Nogapendekin alfa inbakicept + Retifanlimab + SX-682 ETBX-011 ETBX-051 ETBX-061 Nogapendekin alfa inbakicept Retifanlimab SX-682 0 1
ETBX-011 + Nogapendekin alfa inbakicept ETBX-011 Nogapendekin alfa inbakicept 0 1
Gemcitabine + Nab-paclitaxel + Nogapendekin alfa inbakicept Gemcitabine Nab-paclitaxel Nogapendekin alfa inbakicept 0 1
H1299 cell lysate vaccine + Montanide ISA 51 + Nogapendekin alfa inbakicept H1299 cell lysate vaccine Montanide ISA 51 Nogapendekin alfa inbakicept 0 1
HER2 Vaccine + Lenvatinib + Nogapendekin alfa inbakicept + Pembrolizumab HER2 Vaccine Lenvatinib Nogapendekin alfa inbakicept Pembrolizumab 0 1
Ipilimumab + Nogapendekin alfa inbakicept Ipilimumab Nogapendekin alfa inbakicept 0 0
m-ceNK cells + Nogapendekin alfa inbakicept Nogapendekin alfa inbakicept m-ceNK cells 0 1
Nivolumab + Nogapendekin alfa inbakicept Nivolumab Nogapendekin alfa inbakicept 0 2
Nogapendekin alfa inbakicept Nogapendekin alfa inbakicept 0 12
Nogapendekin alfa inbakicept + PD-L1.t-haNK cells + Pembrolizumab Nogapendekin alfa inbakicept PD-L1.t-haNK cells Pembrolizumab 0 2
Nogapendekin alfa inbakicept + Pembrolizumab Nogapendekin alfa inbakicept Pembrolizumab 0 4
Nogapendekin alfa inbakicept + Rituximab Nogapendekin alfa inbakicept Rituximab 0 1


Additional content available in CKB BOOST